1. Home
  2. BTAI
  3. BTAI News

Latest BioXcel Therapeutics Inc. (BTAI) News on November 20, 2025

Looking at the Narrative for BioXcel Therapeutics After Fair Value Reset and Clinical Milestones
BTAI

Simply Wall St.

a day ago

Looking at the Narrative for BioXcel Therapeutics After Fair Value Reset and Clinical Milestones

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates
BTAI

Zacks

8 days ago

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Misses Revenue Estimates

BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer’s Disease
BTAI

GlobeNewswire

8 days ago

BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer’s Disease

BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes
BTAI

GlobeNewswire

a month ago

BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes

BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation
BTAI

GlobeNewswire

a month ago

BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia
BTAI

GlobeNewswire

2 months ago

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia

BTAI

MT Newswires

4 months ago

BioXcel Therapeutics Gets Patent Allowance for Targeted Use of Igalmi in Bipolar, Schizophrenia Patients

BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
BTAI

GlobeNewswire

6 months ago

BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement
BTAI

GlobeNewswire

6 months ago

BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement

BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates
BTAI

Zacks

6 months ago

BioXcel Therapeutics, Inc. (BTAI) Reports Q1 Loss, Lags Revenue Estimates

BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
BTAI

GlobeNewswire

6 months ago

BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

BioXcel Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
BTAI

Simply Wall St.

8 months ago

BioXcel Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates
BTAI

Zacks

8 months ago

BioXcel Therapeutics, Inc. (BTAI) Reports Q4 Loss, Tops Revenue Estimates

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024
BTAI

GlobeNewswire

8 months ago

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight
BTAI

Zacks

8 months ago

Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight

BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
BTAI

GlobeNewswire

8 months ago

BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Why BioXcel Therapeutics, Inc. (BTAI) Soared Last Week
BTAI

Insider Monkey

8 months ago

Why BioXcel Therapeutics, Inc. (BTAI) Soared Last Week

BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
BTAI

GlobeNewswire

8 months ago

BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

ScPharmaceuticals, Inc. (SCPH) Expected to Beat Earnings Estimates: Should You Buy?
BTAI

Zacks

9 months ago

ScPharmaceuticals, Inc. (SCPH) Expected to Beat Earnings Estimates: Should You Buy?

BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering
BTAI

GlobeNewswire

9 months ago

BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering

BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
BTAI

Zacks

9 months ago

BioXcel Therapeutics, Inc. (BTAI) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

BTAI

MT Newswires

9 months ago

Sector Update: Health Care

BioXcel Therapeutics Announces $14 Million Registered Direct Offering
BTAI

GlobeNewswire

9 months ago

BioXcel Therapeutics Announces $14 Million Registered Direct Offering

BTAI

MT Newswires

9 months ago

Top Midday Gainers

BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer’s Dementia
BTAI

GlobeNewswire

9 months ago

BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer’s Dementia

BTAI

MT Newswires

9 months ago

Sector Update: Health Care Stocks Rise in Late Afternoon Trading

BTAI

MT Newswires

9 months ago

Top Midday Gainers

BTAI

MT Newswires

9 months ago

BioXcel Therapeutics Regains Nasdaq Compliance

BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule
BTAI

GlobeNewswire

9 months ago

BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

BTAI

MT Newswires

9 months ago

BioXcel to Implement Reverse Stock Split; Shares Fall

BioXcel Therapeutics Announces Reverse Stock Split
BTAI

GlobeNewswire

9 months ago

BioXcel Therapeutics Announces Reverse Stock Split

BioXcel Therapeutics Provides Clinical and Business Update
BTAI

GlobeNewswire

9 months ago

BioXcel Therapeutics Provides Clinical and Business Update

BioXcel Therapeutics (BTAI) Moves to Buy: Rationale Behind the Upgrade
BTAI

Zacks

a year ago

BioXcel Therapeutics (BTAI) Moves to Buy: Rationale Behind the Upgrade

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering
BTAI

GlobeNewswire

a year ago

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

BioXcel Therapeutics Announces Proposed Public Offering
BTAI

GlobeNewswire

a year ago

BioXcel Therapeutics Announces Proposed Public Offering

BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ...
BTAI

GuruFocus.com

a year ago

BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings Call Highlights: Strategic Trials and ...

BTAI

Thomson Reuters StreetEvents

a year ago

Q3 2024 BioXcel Therapeutics Inc Earnings Call

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates
BTAI

Zacks

a year ago

BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results
BTAI

GlobeNewswire

a year ago

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

What To Expect From BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings
BTAI

GuruFocus.com

a year ago

What To Expect From BioXcel Therapeutics Inc (BTAI) Q3 2024 Earnings

BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s Dementia
BTAI

GlobeNewswire

a year ago

BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s Dementia

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024
BTAI

GlobeNewswire

a year ago

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know
BTAI

Zacks

a year ago

Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know

BioXcel Therapeutics to Present at ThinkEquity Conference
BTAI

GlobeNewswire

a year ago

BioXcel Therapeutics to Present at ThinkEquity Conference

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder
BTAI

GlobeNewswire

a year ago

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation
BTAI

GlobeNewswire

a year ago

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

FMR LLC's Strategic Reduction in BioXcel Therapeutics Inc Shares
BTAI

GuruFocus.com

a year ago

FMR LLC's Strategic Reduction in BioXcel Therapeutics Inc Shares

BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
BTAI

GlobeNewswire

a year ago

BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

BioXcel Therapeutics (BTAI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
BTAI

Zacks

a year ago

BioXcel Therapeutics (BTAI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference
BTAI

GlobeNewswire

a year ago

BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference

BTAI

Thomson Reuters StreetEvents

a year ago

Q2 2024 BioXcel Therapeutics Inc Earnings Call

BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Tops Revenue Estimates
BTAI

Zacks

a year ago

BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Tops Revenue Estimates

BioXcel Therapeutics Reports Second Quarter 2024 Financial Results
BTAI

GlobeNewswire

a year ago

BioXcel Therapeutics Reports Second Quarter 2024 Financial Results

BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024
BTAI

GlobeNewswire

a year ago

BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024

BTAI

MT Newswires

a year ago

BioXcel Therapeutics Shares Rise After Preliminary Q2 Revenue Exceeds Estimates

BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film
BTAI

GlobeNewswire

a year ago

BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film

BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia
BTAI

GlobeNewswire

a year ago

BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia

Media Advisory - Prime Minister's itinerary for Sunday, June 9, 2024
BTAI

CNW Group

a year ago

Media Advisory - Prime Minister's itinerary for Sunday, June 9, 2024

Industry Report: The Cannabis Company that Soared Nearly 100% This Year: What's Behind InterCure's Surge
BTAI

ACCESSWIRE

a year ago

Industry Report: The Cannabis Company that Soared Nearly 100% This Year: What's Behind InterCure's Surge

Russia is doubling down on its de-dollarization efforts as Putin calls to reduce use of 'toxic' currencies
BTAI

Business Insider

a year ago

Russia is doubling down on its de-dollarization efforts as Putin calls to reduce use of 'toxic' currencies

Nvidia May Be an Exciting Stock, but Its 10-for-1 Stock Split -- Like Most Stock Splits -- Is a Nothing Burger
BTAI

Motley Fool

a year ago

Nvidia May Be an Exciting Stock, but Its 10-for-1 Stock Split -- Like Most Stock Splits -- Is a Nothing Burger

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
BTAI

GlobeNewswire

a year ago

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

Unifor members vote to strike at Manitoba Hydro
BTAI

CNW Group

a year ago

Unifor members vote to strike at Manitoba Hydro

Croatia beat Portugal in Euro 2024 warm-up friendly
BTAI

AFP

a year ago

Croatia beat Portugal in Euro 2024 warm-up friendly

Mark Cuban explains how he helped turn 300 of his employees into millionaires
BTAI

Business Insider

a year ago

Mark Cuban explains how he helped turn 300 of his employees into millionaires

BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference
BTAI

GlobeNewswire

a year ago

BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference

BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
BTAI

GlobeNewswire

a year ago

BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2024 Earnings Call Transcript
BTAI

Insider Monkey

2 years ago

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2024 Earnings Call Transcript

BioXcel Therapeutics First Quarter 2024 Earnings: Misses Expectations
BTAI

Simply Wall St.

2 years ago

BioXcel Therapeutics First Quarter 2024 Earnings: Misses Expectations

BTAI

Thomson Reuters StreetEvents

2 years ago

Q1 2024 BioXcel Therapeutics Inc Earnings Call

BioXcel Therapeutics Reports First Quarter 2024 Financial Results
BTAI

GlobeNewswire

2 years ago

BioXcel Therapeutics Reports First Quarter 2024 Financial Results

BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024
BTAI

GlobeNewswire

2 years ago

BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024

BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
BTAI

GlobeNewswire

2 years ago

BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting

BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential
BTAI

GlobeNewswire

2 years ago

BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential

BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia
BTAI

GlobeNewswire

2 years ago

BioXcel Therapeutics Announces TRANQUILITY In-Care Pivotal Phase 3 Trial Plan With BXCL501 for Agitation Associated With Alzheimer’s Dementia

BioXcel Therapeutics Announces $25 Million Registered Direct Offering
BTAI

GlobeNewswire

2 years ago

BioXcel Therapeutics Announces $25 Million Registered Direct Offering

BioXcel Therapeutics Full Year 2023 Earnings: Revenues Disappoint
BTAI

Simply Wall St.

2 years ago

BioXcel Therapeutics Full Year 2023 Earnings: Revenues Disappoint

BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine
BTAI

GlobeNewswire

2 years ago

BioXcel Therapeutics Announces European Patent Office’s Grant of Patent for Method of Treating Agitation in Dementia Using Sublingual Dexmedetomidine

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call Transcript
BTAI

Insider Monkey

2 years ago

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call Transcript

BTAI

Thomson Reuters StreetEvents

2 years ago

Q4 2023 BioXcel Therapeutics Inc Earnings Call

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023
BTAI

GlobeNewswire

2 years ago

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023

BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024
BTAI

GlobeNewswire

2 years ago

BioXcel Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024

15 Hot Penny Stocks On the Move
BTAI

Insider Monkey

2 years ago

15 Hot Penny Stocks On the Move

BioXcel Therapeutics Announces Termination of Proposed Public Offering
BTAI

GlobeNewswire

2 years ago

BioXcel Therapeutics Announces Termination of Proposed Public Offering

BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)
BTAI

GlobeNewswire

2 years ago

BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)

BioXcel Therapeutics Announces Proposed Public Offering
BTAI

GlobeNewswire

2 years ago

BioXcel Therapeutics Announces Proposed Public Offering

BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®
BTAI

GlobeNewswire

2 years ago

BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®

BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine
BTAI

GlobeNewswire

2 years ago

BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine

Baillie Gifford Bolsters Stake in American Superconductor Corp
BTAI

GuruFocus.com

2 years ago

Baillie Gifford Bolsters Stake in American Superconductor Corp

Firms in Brazil Turn to Oracle for Security, Service, Speed
BTAI

Business Wire

2 years ago

Firms in Brazil Turn to Oracle for Security, Service, Speed

Westwood Holdings Group, Inc. to Host Fourth Quarter and Fiscal Year 2023 Conference Call/Webcast
BTAI

GlobeNewswire

2 years ago

Westwood Holdings Group, Inc. to Host Fourth Quarter and Fiscal Year 2023 Conference Call/Webcast

Chuck Royce Adjusts Position in Hurco Companies Inc
BTAI

GuruFocus.com

2 years ago

Chuck Royce Adjusts Position in Hurco Companies Inc

BTAI

Newsfile

2 years ago

Heritage Global, Inc. to Present at The Microcap Conference on Wednesday, January 31 and Thursday, February 1, 2024

Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why
BTAI

Zacks

2 years ago

Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why

Duluth Holdings Inc. Announces Appointment of Heena Agrawal as Chief Financial Officer
BTAI

GlobeNewswire

2 years ago

Duluth Holdings Inc. Announces Appointment of Heena Agrawal as Chief Financial Officer

Best Momentum Stock to Buy for January 19th
BTAI

Zacks

2 years ago

Best Momentum Stock to Buy for January 19th

LivePerson, Inc.'s (NASDAQ:LPSN) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures
BTAI

Simply Wall St.

2 years ago

LivePerson, Inc.'s (NASDAQ:LPSN) latest 15% decline adds to one-year losses, institutional investors may consider drastic measures

Spotting Winners: Noodles (NASDAQ:NDLS) And Modern Fast Food Stocks In Q3
BTAI

StockStory

2 years ago

Spotting Winners: Noodles (NASDAQ:NDLS) And Modern Fast Food Stocks In Q3

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
BTAI

GlobeNewswire

2 years ago

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

Heritage Global, Inc. to Present at the Sequire Investor Summit in Puerto Rico
BTAI

GlobeNewswire

2 years ago

Heritage Global, Inc. to Present at the Sequire Investor Summit in Puerto Rico

Share on Social Networks: